--- title: "Paul Mahon's UTHR May Sale: Monthly Exercise Cadence Decoded" type: news slug: uthr-paul-mahon-may-7-monthly-option-exercise-cadence canonical_url: https://13finsight.com/news/uthr-paul-mahon-may-7-monthly-option-exercise-cadence published_at: 2026-05-13T00:42:36.153Z updated_at: 2026-05-13T00:42:39.043Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 875 locale: en source: 13F Insight --- # Paul Mahon's UTHR May Sale: Monthly Exercise Cadence Decoded > United Therapeutics EVP Paul Mahon's May 7 Form 4 reads as a $5M open-market sale at $585-$597 — but the full transaction tape shows a programmatic monthly exercise-and-sell pattern, not a discretionary view on the stock. Paul Mahon, EVP & General Counsel at United Therapeutics, filed Form 4 on May 7 disclosing exercise of 8,300 options at the $146.03 strike and sale of 8,220 shares in the open market at prices between $582.86 and $597.54. The headline value of the sales is roughly $4.8M, and the math on the embedded options gain — strike at $146.03 versus market at ~$590 — is roughly $444 per share realized on the underlying. As a single filing, it looks like a senior executive cashing out at a multi-year high. As a pattern, it looks like something much more boring: a programmatic monthly compensation cycle that has been running for at least the past 30 days.That distinction matters because Mahon's career sale history on this Form 4 docket totals $259M of cumulative sales across 1,832 transactions — a number that reads ominous in a headline but reflects more than two decades of accumulated compensation flow at a company whose stock has compounded through the same window. The May 7 filing is consistent with that pattern, not a deviation from it.The cadence, not the size, is the signalThe Form 4 transaction tape for Mahon shows the same shape every month:May 7, 2026: M (option exercise) 8,300 shares at $146.03 strike, then S (open-market sale) 8,220 shares between $582.86 and $597.54.April 16, 2026: M 8,300 shares at $146.03, then S at $574.03-$578.21.April 2, 2026: M 8,300 shares at $146.03, then S at $569.61-$571.61.That is the signature of a Rule 10b5-1 trading plan (or its functional equivalent — a pre-scheduled compensation-driven exercise schedule). The exercise price is constant ($146.03 — meaning these options were granted from a single vesting tranche), the cadence is roughly bi-weekly, and the sale price moves with the market rather than against it. Form 4 doesn't always explicitly flag the 10b5-1 plan in the underlying XBRL — but the pattern is unmistakable: this is a programmatic schedule, not a discretionary trade.The implication for narrative: this is not a CEO unloading stock ahead of bad news, and it is not a senior executive monetizing on a private thesis about UTHR's pulmonary hypertension franchise softening. It is a compensation pipeline draining into a brokerage account on a clock.What Mahon's filings do sayThree substantive readouts from the disclosure tape:The options grant economics. A $146.03 strike means these options were issued when UTHR was trading roughly there — likely a 2017-2018 vintage grant given UTHR's historical price chart. The fact that the strike is constant across recent exercises says they are all from the same grant tranche, exercised in stages as they vest or as plan rules permit. Each exercise locks ~$444 per share, or roughly $3.7M of intrinsic value per cycle, before tax. That's the structural payout, not a market timing call.The post-sale share balance. Mahon's reported direct beneficial ownership after the May 7 transactions is 300 shares. That is a small number for a senior officer, but it does not imply he has divested his economic interest in UTHR — Mahon's beneficial ownership picture also includes unvested RSUs, unexercised options, and any indirect holdings through trusts not surfaced in Table I. The Form 4 reads "300 shares" because that is the residual Class A position after the latest cycle; it is not a stake-size signal.What the broader 13F tape says. Two non-trivial Schedule 13G filings have landed on UTHR in 2026:April 30, 2026: Vanguard Capital Management LLC disclosed a 5.19% stake (2.28M shares) — a passive index increment, not a conviction signal, but worth marking as the largest 2026 ownership shift in the name.February 10, 2026: Wellington Management Group LLP disclosed a 5.70% stake (2.44M shares). Wellington is an active manager; a fresh crossing of the 5% threshold on a biotech in this category is the institutional-conviction read you should weigh more heavily than Mahon's compensation flow.Read together, the 13G tape is the more informative document: active institutional accumulation has continued through the senior officer compensation schedule. Wellington's cross above 5% in February and Vanguard's index-fund accumulation in April mean the market is buying UTHR at the same prices Mahon is selling into. Whatever Mahon's plan reflects, it is not consensus.What to watch from hereThree concrete anchors:Next earnings window: UTHR's Q2 2026 release is the next catalyst that could change the compensation-vs-conviction read. If the company prints inline and the active-manager 13F base holds or grows in the August reporting window, Mahon's exercises remain pure plan noise. If active managers trim and earnings disappoint, the executive selling becomes a narrative companion rather than a structural footnote.Plan-renewal disclosures: Senior officers periodically refresh 10b5-1 plans, typically via Form 4 footnote disclosures or 8-K filings. A plan amendment from Mahon's filing history in the next 60 days would be the first signal that the cadence is changing.Wellington 13G/A activity: Wellington is an active manager, not a passive index. Any 13G/A amendment from them in 2026Q2 — particularly an exit below 5% — would be the more meaningful read on UTHR than any executive sale, and would appear in our activist filings feed first.For the underlying SEC record, Mahon's Form 4 filings are available at EDGAR CIK 0001231589. Cross-reference his career transaction pattern on the Mahon insider profile page, or browse smart-money insights for active-manager activity in the biotech segment. ## FAQ ### What did Paul Mahon sell on May 7? United Therapeutics EVP & General Counsel Paul Mahon disclosed on Form 4 dated May 7, 2026 that he exercised 8,300 stock options at a strike of $146.03 and sold 8,220 shares in the open market at prices between $582.86 and $597.54, for total proceeds of roughly $4.8 million. The transaction is the latest cycle in a recurring exercise-and-sell pattern visible across his Form 4 history. ### Is Paul Mahon's UTHR sale a 10b5-1 plan trade? The May 7 filing is consistent with a Rule 10b5-1 plan or a functionally equivalent pre-scheduled compensation exercise. The recurring monthly cadence, constant option strike of $146.03, and structurally identical transaction shape across April 2 and April 16 filings all point to a programmatic schedule rather than discretionary trading on a private view of UTHR. ### How much does Paul Mahon own of UTHR? Mahon's direct Class A common holdings after the May 7 transactions were 300 shares per Form 4 Table I. That residual figure does not represent his total economic interest, which can include unvested RSUs, unexercised options, and any indirect holdings through trusts not disclosed in Form 4 Table I. Total cumulative sale value across his career on this docket is approximately $259M across 1,832 transactions. ### Who else owns United Therapeutics stock? Two 2026 Schedule 13G filings stand out: Wellington Management Group disclosed a 5.70% stake (2.44M shares) on February 10, 2026, and Vanguard Capital Management LLC disclosed a 5.19% stake (2.28M shares) on April 30, 2026. Wellington's filing is a fresh institutional crossing of the 5% threshold from an active manager — a stronger signal than Vanguard's index-fund-driven accumulation. --- Source: 13F Insight — https://13finsight.com/news/uthr-paul-mahon-may-7-monthly-option-exercise-cadence Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-05-13T00:42:39.043Z